GAPP Review Panel

GAPP_Committee_BurtDavid Burt, PhD
President of D. S. Burt, R&D Consulting

Dr. David Burt has more than 25 years experience in multinationals and start-ups within the vaccine industry holding senior scientific management positions including Director of R&D, North America for GSK Biologicals, Vice-President, Research at ID Biomedical Corporation of Quebec and Vice-President, Research for Intellivax International. Before joining Intellivax, David spent 8 years leading teams in vaccine R&D at Pasteur Merieux Connaught (now Sanofi-Pasteur) in Toronto.
David is currently President of D. S. Burt, R&D Consulting, offering independent consulting advice in vaccine and biologics research and development.
Dr. Burt was previously a research scientist at the National Institute for Medical Research, London, England. He received his Ph.D. in Immunology from the University of Birmingham and a BSc. in Biological chemistry from the Essex University, UK. He has published over 40 peer-reviewed scientific manuscripts and is co-inventor on 7 patents.
David has been an advisory board member of the CIHR Institute of Infection and Immunity and a board member of PREVENT, a Centre of Excellence for Commercialization and Research (CERC) established through the Canadian Networks of Centers of Excellence program.
David has received various honors including the Harry Jerome Award for Health Sciences in 2006 for his contributions to scientific endeavor and his activities in promoting science in the community.

GAPP_Committee_CanningKevin Canning, PhD
Director, Technology and Venture Development, Life Sciences at MaRS Innovation

As Director, Technology & Venture Development for the life sciences, Kevin develops strategies to bring medicines invented in the local scientific community to patients. He performs technical and market due diligence and evaluates the competitive positioning and advantages of new technologies to support and expand MaRS Innovation’s portfolio. He develops business, technical, strategic and financing plans to bring new start-up ventures to fruition. He also actively markets technologies to support licensing, co-development and other commercialization transactions.
Kevin has over fifteen years of leadership and people-management experience in roles of increasing responsibility in the pharmaceutical industry. He has worked in, and led teams in, basic research and genetics, research alliances/scouting, venture capital, clinical research, statistics, epidemiology, data management, medical development, commercial assessment, medical affairs, outsourcing and contracts, strategy and operations. Prior to joining MaRS Innovation Kevin spent more than three years at GSK China R&D in Shanghai as Director, Strategy and Operations.
Kevin holds a Ph.D. and an H.B.Sc. in Physiology, both from Western University. He holds an M.B.A. from the Ivey Business School, Western University and was recognized as an Ivey Scholar in this program.

GAPP_Committee_ClimieShane Climie, PhD
Principal, Popper and Company

Shane Climie, Ph.D. is a Principal with Popper and Company, which is focused on building life science organizations by meeting the needs of entrepreneurial, life science startups and the investors that support these early stage organizations. Popper and Co provides expertise in the areas of business management, marketing strategy and technology or opportunity assessment. Dr. Climie has more than 20 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery and technology development, and has designed, negotiated and managed many R&D collaborations. He has extensive experience in technology evaluation, technology development and strategic planning. Prior to joining Popper and Co. Dr. Climie held several positions at Protana (formerly MDS Proteomics) including Senior Vice President of Science Strategy and Business Development, Senior Vice-President of Research Collaborations, and Vice-President of Proteomics and Business Development. From 1999 to 2000, Dr. Climie was co-founder, Vice-President and Chief Technology Officer of MDS Ocata. In 1999 Dr. Climie was a Visiting Research Scientist at the Samuel Lunenfeld Research Institute. From 1990 to 1999, Dr. Climie held several managerial positions at Allelix Biopharmaceuticals, Inc. (Now NPS Pharmaceuticals Inc., (Nasdaq:NPSP) including Principal Scientist.  Dr. Climie did postdoctoral work at the University of California at San Francisco with Dr. Daniel Santi, and received a Ph.D. in medical biophysics from the University of Toronto and a B.Sc. in biology from the University of Waterloo.

GAPP_Committee_FoxallRoger Foxall, PhD
Life Science Strategies Inc., Surrey, BC

Roger obtained his B.Sc.(Eng.) at the Imperial College of  Science and Technology, University of London. He obtained his Ph.D. in Physics at the Cavendish Laboratory of the University of Cambridge, followed by postdoctoral studies at the University of Oxford.  He moved to Ottawa in 1968 to take up a Research Officer position at the National Research Council.  Following a series of assignments that prepared him for a career in research management, Roger became Director of the NRC Laboratory in Halifax in 1984 and was its Director General from 1990 until April 1998. Roger moved to British Columbia in July 1998, and established a consulting company focused on the life sciences. From August 2000 through January 2002 he served as the founding President and CEO of Genome British Columbia. Roger then served as Executive Vice President Research until December 2003 and Executive Vice President Corporate Development until August 2005. Roger is now CEO of Life Science Strategies Inc specializing in strategic analysis and advice regarding programs and projects in the genome sciences. Recent clients include Genome Canada and the genome centres in Alberta, Atlantic Canada, British Columbia, Ontario and Quebec, Children’s Hospital of Eastern Ontario and the PROOF Centre for Excellence in Commercialization and Research.

GAPP_Committee_KellyJohn Kelly, PhD
CEO, KeliRo Company Inc.

John Kelly is currently the CEO at KeliRo Company Inc., which supports business development in domestic and international agricultural markets.  He is formerly vice-president of the Erie Innovation and Commercialization with the Ontario Fruit & Vegetable Growers’ Association. Throughout his career, he has sought to enable innovation and diversify agriculture and food opportunities throughout Canada and elsewhere. He has a wealth of experience in the private and public sector and has held various executive and Board of Director positions with start-ups and multinational companies, including Life Sciences Ontario, MaRS Landing, Land O’ Lakes, Ralston Purina, Rhone-Poulenc Canada Inc. and Aventis CropSciences Inc., as well as the Ontario Ministry of Agriculture, Food and Rural Affairs. Throughout his career, he has been focused on innovation, development and implementation, actively advancing products and technologies in agriculture, food, biotechnology, pharma and the bioeconomy sectors.
John holds a B.Sc. (Agr). and Ph.D. from the University of Guelph and a Master of Science from the University of Alberta. John is also Adjunct Professor in the Department of Animal and Poultry Science and the Department of Plant Agriculture at the University of Guelph.
John has been involved in the training programs at York University through the Asian Business & Management Program for more than 5 years, having trained many individuals from that region. These training programs have provided the opportunity for Canada to share some of its expertise with international delegations.  They are very concentrated programs with lots of breadth and add significant value to participants as they go through them.

GAPP_Committee_LundieMark Lundie
Head, Strategic Research Partnerships (Ontario)
Director, Medical Affairs, Rare Diseases (National), Pfizer Canada Inc.

Mark Lundie is currently Head, Strategic Research Partnerships (Ontario) and Director, Medical Affairs, Rare Diseases (National) with Pfizer Canada Inc.  He received a Bachelors of Science from the University of Waterloo ((1986) followed by a MSc from Queen’s University (1989) and a doctorate degree from Department of Pharmacology & Toxicology at Queen’s University in 1995. He joined the pharmaceutical industry with Pfizer Canada in 1997 and over the past 16 years has held a number of positions of increasing responsibility within the Pfizer Canada Medical Division, including brand medical support, clinical research management, field medical roles and external R&D scouting.  He currently serves on the Board of Clinical Trials Ontario, the Center for Probe Development & Commercialization and AllerGEN NCE. Within his current mandate Mark has supported the development of partnerships with Pfizer Research Units and Ontario based institutes such as the Ontario Institute of Cancer Research, the Structural Genomics Consortium, MaRS Innovation and the Center for Commercialization of Regenerative Medicine.

GAPP_Committee_StiffJamie Stiff
Managing Director, Genesys Capital

Mr. Stiff joined Genesys Capital in 2002 and became partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in nine early stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Past board affiliations include Allostera Pharma Inc., gIcare Pharma Inc., Interface Biologics, Inc., Matregen Corp, Naurex Inc. (acquired by Allergan NYSE:AGN), NeurAxon Inc., StemPath Inc., Therapeutic Monitoring Systems Inc. and Zelos Therapeutics Inc.
Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.

GAPP_Committee_UnderdownBrian Underdown, PhD
Managing Director, Technology Investing, Lumira Capital

Brian Underdown has served on the OGI’s Board of Directors since 2004 and as Chair since 2011. His academic research, extensive experience in venture investment, and operational knowledge in commercial biotechnology enhance OGI’s efforts to facilitate and catalyse the impact of genomics research. Dr. Underdown is Managing Director of Lumira Capital, where he concentrates on investments in North American therapeutics companies at all stages of development.  He had earlier been Assistant Vice-President for Research at Pasteur Merieux Connaught, where he headed the Canadian Universities Research program and several global programs to develop vaccines. During his academic career, he was Associate Dean of Research at the University of Toronto’s Faculty of Medicine and at McMaster University’s Faculty of Health Sciences.
Dr. Underdown has held senior positions on national and international bodies concerned with science policy and university-industry collaboration. He has served on boards of such life sciences companies as Argos Therapeutics, Ception Therapeutics, Cytochroma Inc., Golden Horseshoe Biotechnology Network, ID Biomedical, Nysa Membrane Technologies, Trillium Therapeutics, Transmolecular Therapeutics, and Viron Therapeutics. He received his PhD in Immunology from McGill University and undertook postdoctoral studies at Washington University School of Medicine in St. Louis.